Cargando…
The authors reply: Letter on: "Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy" by Zhou et al.
Autores principales: | Zhou, Haiyan, Muntoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567137/ https://www.ncbi.nlm.nih.gov/pubmed/32705767 http://dx.doi.org/10.1002/jcsm.12608 |
Ejemplares similares
-
Comment on: “Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy” by Zhou et al.
por: Chen, Tai‐Heng
Publicado: (2020) -
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
por: Zhou, Haiyan, et al.
Publicado: (2020) -
Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
por: Sintusek, Palittiya, et al.
Publicado: (2016) -
Reply to comment on: A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides
por: Dominov, Janice A, et al.
Publicado: (2015) -
Reply to: The need for evidence‐based treatment decisions in spinal muscular atrophy type 0
por: Mercuri, Eugenio, et al.
Publicado: (2021)